原发性Sjögren综合征进行性肺纤维化的临床特征和危险因素:一项病例对照研究。

IF 2 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Risk Management and Healthcare Policy Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.2147/RMHP.S533705
Jianping Diao, Lin Qiao, Xinwang Duan, Min Hui, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Dong Xu
{"title":"原发性Sjögren综合征进行性肺纤维化的临床特征和危险因素:一项病例对照研究。","authors":"Jianping Diao, Lin Qiao, Xinwang Duan, Min Hui, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Dong Xu","doi":"10.2147/RMHP.S533705","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to investigate the clinical characteristics and identify risk factors associated with progressive pulmonary fibrosis (PPF) in individuals diagnosed with primary Sjögren's syndrome (pSS).</p><p><strong>Methods: </strong>A retrospective case-control study was conducted from individuals with pSS-associated interstitial lung disease (pSS-ILD) registered in the Chinese Rheumatism Data Center between June 2010 and October 2023. Participants were categorized into two groups: those with PPF (pSS-PPF) and those without PPF (pSS-non-PPF). Comparative analyses were performed on clinical manifestations, laboratory parameters, pulmonary function, and treatment history between the two groups.</p><p><strong>Results: </strong>Sixty-six individuals with pSS-ILD were included, of whom 29 met the criteria for PPF. Compared to pSS-non-PPF group, the pSS-PPF group demonstrated a higher rate of expectoration (48.3% vs 16.2%, <i>p</i> = 0.005) and crackles on auscultation (41.4% vs 13.5%, <i>p</i> = 0.01), but lower rates of parotid gland enlargement (3.4% vs 32.4%, <i>p</i> = 0.003), and arthritis (6.9% vs 27%, <i>p</i> = 0.035). Additionally, the incidence rate of the subjects suffering xerophthalmia and xerostomia in the PPF group was lower (24.1% vs 2.7%, <i>p</i> = 0.023). Pulmonary function testing showed significantly reduced forced vital capacity percentage predicted (83.6±15.6 vs 91.3±14.6, <i>p</i> = 0.042) and diffusing capacity of the lung for carbon monoxide percentage predicted (DLCO%, 54.2±21.5 vs 68.5±13.6, <i>p</i> = 0.003) in the PPF group. Multivariate logistic regression identified a baseline DLCO% < 60% as an independent risk factor for PPF. Parotid gland enlargement and arthritis were potentially protective. The predictive model demonstrated good performance, with an area under the curve of 0.821 (95% CI: 0.716~0.925, <i>p</i> < 0.001). The sensitivity was 58.6% and the specificity was 91.7%.</p><p><strong>Conclusion: </strong>A baseline DLCO% < 60% is an independent predictor of PPF in individuals with pSS. The developed predictive model shows strong discriminatory ability, while further validation in larger cohorts is warranted.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"3017-3028"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441109/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.\",\"authors\":\"Jianping Diao, Lin Qiao, Xinwang Duan, Min Hui, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Dong Xu\",\"doi\":\"10.2147/RMHP.S533705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aims to investigate the clinical characteristics and identify risk factors associated with progressive pulmonary fibrosis (PPF) in individuals diagnosed with primary Sjögren's syndrome (pSS).</p><p><strong>Methods: </strong>A retrospective case-control study was conducted from individuals with pSS-associated interstitial lung disease (pSS-ILD) registered in the Chinese Rheumatism Data Center between June 2010 and October 2023. Participants were categorized into two groups: those with PPF (pSS-PPF) and those without PPF (pSS-non-PPF). Comparative analyses were performed on clinical manifestations, laboratory parameters, pulmonary function, and treatment history between the two groups.</p><p><strong>Results: </strong>Sixty-six individuals with pSS-ILD were included, of whom 29 met the criteria for PPF. Compared to pSS-non-PPF group, the pSS-PPF group demonstrated a higher rate of expectoration (48.3% vs 16.2%, <i>p</i> = 0.005) and crackles on auscultation (41.4% vs 13.5%, <i>p</i> = 0.01), but lower rates of parotid gland enlargement (3.4% vs 32.4%, <i>p</i> = 0.003), and arthritis (6.9% vs 27%, <i>p</i> = 0.035). Additionally, the incidence rate of the subjects suffering xerophthalmia and xerostomia in the PPF group was lower (24.1% vs 2.7%, <i>p</i> = 0.023). Pulmonary function testing showed significantly reduced forced vital capacity percentage predicted (83.6±15.6 vs 91.3±14.6, <i>p</i> = 0.042) and diffusing capacity of the lung for carbon monoxide percentage predicted (DLCO%, 54.2±21.5 vs 68.5±13.6, <i>p</i> = 0.003) in the PPF group. Multivariate logistic regression identified a baseline DLCO% < 60% as an independent risk factor for PPF. Parotid gland enlargement and arthritis were potentially protective. The predictive model demonstrated good performance, with an area under the curve of 0.821 (95% CI: 0.716~0.925, <i>p</i> < 0.001). The sensitivity was 58.6% and the specificity was 91.7%.</p><p><strong>Conclusion: </strong>A baseline DLCO% < 60% is an independent predictor of PPF in individuals with pSS. The developed predictive model shows strong discriminatory ability, while further validation in larger cohorts is warranted.</p>\",\"PeriodicalId\":56009,\"journal\":{\"name\":\"Risk Management and Healthcare Policy\",\"volume\":\"18 \",\"pages\":\"3017-3028\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Risk Management and Healthcare Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/RMHP.S533705\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S533705","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在探讨原发性Sjögren综合征(pSS)患者的临床特征,并确定与进行性肺纤维化(PPF)相关的危险因素。方法:对2010年6月至2023年10月在中国风湿病数据中心登记的pss相关间质性肺病(pSS-ILD)患者进行回顾性病例对照研究。参与者被分为两组:有PPF的(pSS-PPF)和没有PPF的(pss -非PPF)。比较分析两组患者的临床表现、实验室指标、肺功能及治疗史。结果:纳入66例pSS-ILD患者,其中29例符合PPF标准。与pSS-PPF组相比,pSS-PPF组的咳痰率(48.3%比16.2%,p = 0.005)和听诊声音响(41.4%比13.5%,p = 0.01)较高,但腮腺肿大(3.4%比32.4%,p = 0.003)和关节炎(6.9%比27%,p = 0.035)的发生率较低。此外,PPF组患者出现干眼和口干的发生率较低(24.1% vs 2.7%, p = 0.023)。肺功能测试显示,PPF组预测的强制肺活量百分比(83.6±15.6比91.3±14.6,p = 0.042)和预测的肺弥散量一氧化碳百分比(DLCO%, 54.2±21.5比68.5±13.6,p = 0.003)显著降低。多因素logistic回归确定基线DLCO% < 60%为PPF的独立危险因素。腮腺肿大和关节炎具有潜在的保护作用。预测模型效果良好,曲线下面积为0.821 (95% CI: 0.716~0.925, p < 0.001)。敏感性为58.6%,特异性为91.7%。结论:基线DLCO% < 60%是pSS患者PPF的独立预测因子。开发的预测模型显示出很强的区分能力,但需要在更大的队列中进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.

Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.

Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.

Objective: This study aims to investigate the clinical characteristics and identify risk factors associated with progressive pulmonary fibrosis (PPF) in individuals diagnosed with primary Sjögren's syndrome (pSS).

Methods: A retrospective case-control study was conducted from individuals with pSS-associated interstitial lung disease (pSS-ILD) registered in the Chinese Rheumatism Data Center between June 2010 and October 2023. Participants were categorized into two groups: those with PPF (pSS-PPF) and those without PPF (pSS-non-PPF). Comparative analyses were performed on clinical manifestations, laboratory parameters, pulmonary function, and treatment history between the two groups.

Results: Sixty-six individuals with pSS-ILD were included, of whom 29 met the criteria for PPF. Compared to pSS-non-PPF group, the pSS-PPF group demonstrated a higher rate of expectoration (48.3% vs 16.2%, p = 0.005) and crackles on auscultation (41.4% vs 13.5%, p = 0.01), but lower rates of parotid gland enlargement (3.4% vs 32.4%, p = 0.003), and arthritis (6.9% vs 27%, p = 0.035). Additionally, the incidence rate of the subjects suffering xerophthalmia and xerostomia in the PPF group was lower (24.1% vs 2.7%, p = 0.023). Pulmonary function testing showed significantly reduced forced vital capacity percentage predicted (83.6±15.6 vs 91.3±14.6, p = 0.042) and diffusing capacity of the lung for carbon monoxide percentage predicted (DLCO%, 54.2±21.5 vs 68.5±13.6, p = 0.003) in the PPF group. Multivariate logistic regression identified a baseline DLCO% < 60% as an independent risk factor for PPF. Parotid gland enlargement and arthritis were potentially protective. The predictive model demonstrated good performance, with an area under the curve of 0.821 (95% CI: 0.716~0.925, p < 0.001). The sensitivity was 58.6% and the specificity was 91.7%.

Conclusion: A baseline DLCO% < 60% is an independent predictor of PPF in individuals with pSS. The developed predictive model shows strong discriminatory ability, while further validation in larger cohorts is warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Risk Management and Healthcare Policy
Risk Management and Healthcare Policy Medicine-Public Health, Environmental and Occupational Health
CiteScore
6.20
自引率
2.90%
发文量
242
审稿时长
16 weeks
期刊介绍: Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include: Public and community health Policy and law Preventative and predictive healthcare Risk and hazard management Epidemiology, detection and screening Lifestyle and diet modification Vaccination and disease transmission/modification programs Health and safety and occupational health Healthcare services provision Health literacy and education Advertising and promotion of health issues Health economic evaluations and resource management Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信